ResearcherAccuronix Therapeutics, Inc.Active in the last 2 years
Dirk M. Spitzer
Matched on ORCID iD 0000-0003-3949-1815; OpenAlex author ID A5013020518; NIH RePORTER profile ID 10644772. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 3
- Labs led
- 2
- Collaborators
- 12
2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 grant · 2020: none · 2021: 1 grant · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 grant
Papers 6
- Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochond… Co-author DOI 10.1186/s12885-016-3040-4↗
- The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-016-0470-4↗
- Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Co-author DOI 10.18632/oncotarget.9551↗
- Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. First author DOI 10.1016/j.molonc.2014.03.005↗
- Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. First author DOI 10.1016/j.surg.2012.05.014↗
- Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. Co-author DOI 10.1186/1756-9966-31-41↗
Grants 3
- Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy R01CA276378↗
- On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49 R01CA163764↗
- Advancement of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC) R41CA239853↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- William G. Hawkins · 6 shared papers, 2 shared grants, 2012–2026 · strength 2.13
- Grant Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy R01CA276378↗
- Grant On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW … R01CA163764↗
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- John R. Hornick · 4 shared papers, 2012–2017 · strength 0.19
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Paper Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. DOI 10.1016/j.surg.2012.05.014↗
- Yassar M. Hashim · 3 shared papers, 2014–2017 · strength 0.16
- Paper The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. DOI 10.1186/s13046-016-0470-4↗
- Paper Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic canc… DOI 10.18632/oncotarget.9551↗
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Peter S. Goedegebuure · 3 shared papers, 2012–2014 · strength 0.12
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Paper Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. DOI 10.1016/j.surg.2012.05.014↗
- Paper Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic canc… DOI 10.1186/1756-9966-31-41↗
- Carmen Abate · 2 shared papers, 2012–2017 · strength 0.11
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic canc… DOI 10.1186/1756-9966-31-41↗
- Maria Laura Pati · 1 shared paper, 2017 · strength 0.08
- Mauro Niso · 1 shared paper, 2017 · strength 0.08
- Timothy M. Nywening · 1 shared paper, 2016 · strength 0.05
- Kerri A. Ohman · 1 shared paper, 2016 · strength 0.05
- David Arthur Tuveson · 1 shared paper, 2016 · strength 0.05
- Hervé Tiriac · 1 shared paper, 2016 · strength 0.05
- David G DeNardo · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.